Stifel raises FTAI Aviation stock price target to $147 on PMA approval outlook

FTAI Aviation (NASDAQ:FTAI) reported robust Q2 2025 results, significantly surpassing analyst expectations with adjusted EBITDA of $347 million and EPS of $1.57. Despite Q2 aerospace margin compression due to large airline orders, Stifel raised its price target to $147, maintaining a Buy rating, while Benchmark reiterated its $300 target. Analysts are bullish on FTAI's outlook, anticipating substantial margin expansion to 40% by year-end and 45% by 2026, driven by increased module production, piece part repairs, and the expected October approval of key Parts Manufacturer Approval (PMA) parts, which is seen as a significant catalyst for future profitability and cash flow.

Analysis

FTAI Aviation (FTAI) demonstrated significant operational strength in its second-quarter 2025 results, decisively beating analyst expectations. The company reported an adjusted EBITDA of $347 million against a forecast of $284 million, and an EPS of $1.57, which was a 21.71% surprise over the expected $1.29. This outperformance was driven by sequential growth in both its Aerospace Products and Aviation Leasing segments, which contributed $165 million and $199 million to adjusted EBITDA, respectively. Despite a temporary depression in aerospace margins due to better pricing for a large airline customer, analyst sentiment remains strongly positive. Stifel raised its price target to $147 from $123, and Benchmark reiterated its $300 target, with both firms maintaining Buy ratings. The bullish outlook is underpinned by management's clear strategy for margin expansion, guiding for 40% margins by year-end and approximately 45% in 2026. This growth is expected to be fueled by increased module production, piece part repairs, and the anticipated approval of a key Parts Manufacturer Approval (PMA) part in October, which Stifel identifies as a primary near-term catalyst.

Key Decisions for Investors

• Given the strong Q2 earnings beat and bullish analyst revisions, investors may consider the current positive momentum supportive of maintaining or initiating long positions.
• The expected Parts Manufacturer Approval (PMA) in October represents a significant near-term catalyst; it is crucial to monitor for this approval as it is expected to unlock the guided margin expansion.
• Investors should track the company's ability to execute on its margin guidance of 40% by year-end, as delivering on this projection is key to validating the current bullish thesis and justifying further stock appreciation.